Brief: Lisata Therapeutics' Cancer Drug Gets US FDA Orphan Drug Designation
09/04/2024 13:41
April 9 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS ANNOUNCES U.S. FDA ORPHAN DRUG
DESIGNATION
GRANTED TO LSTA1 FOR THE TREATMENT OF OSTEOSARCOMA
Source text for Eikon: ID:nGNX1Hd561
Further company coverage: LSTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal